Successful Phase III OLYMPIAD trial for Lynparza (olaparib) as a treatment of BRCA-mutated metastatic breast cancer . - Astra Zeneca

AstraZeneca announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin).

BRCA-mutated metastatic breast cancer is a disease with a high unmet need and these findings are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. Initial findings from the OLYMPIAD study indicate that the safety profile of Lynparza was consistent with previous studies. A full evaluation of the OLYMPIAD data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting. Astra Zeneca will be working with regulatory authorities to make Lynparza available to patients with this type of breast cancer.